Curriculum
Course Description:
To investigate changes in excipient grade and the impact of these changes on bioequivalence and bioavailability, FDA has an ongoing research program for generic drugs for various product categories to steer development of guidances and recommendations to industry on excipient selection for generic products.
Featuring Stephanie Choi, Ph.D., U.S. FDA
Access Duration:Access to this course expires 60 days from the date of registration or until you mark the course ‘Complete’ – whichever occurs first.